Zhi Zhang1, Yi-Chao Zhao1, Yuan Cheng1, Guo-Deng Jian1, Ming-Xin Pan1, Yi Gao1. 1. Zhi Zhang, Yuan Cheng, Ming-Xin Pan, Yi Gao, Second Department of Hepatobiliary, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, Guangdong Province, China.
Abstract
AIM: To evaluate a hybrid bioartificial liver support system (HBALSS) in cynomolgus monkeys with acute liver failure. METHODS: To establish a model of acute liver failure, 0.3 g/kg of D-galactosamine was injected intravenously into cynomolgus monkeys. Chinese human liver cells were introduced into a perfusion bioreactor to carry out hybrid bioartificial liver support treatment. Forty-eight hours after the injection, one group of cynomolgus monkeys received HBALSS care, and a second experimental group received no treatment. Clinical manifestations of all animals, survival time, liver and kidney functions and serum biochemistry changes were recorded. Simultaneous detection of the number, viability and function of hepatocytes in the hybrid bioartificial liver were also performed. RESULTS: Forty-eight hours after the injection of D-galactosamine, serum biochemistry levels were significantly increased, whereas albumin levels and the Fischer index were significantly reduced compared to baseline (all Ps < 0.05). Of the ten monkeys in the HBALSS treatment group, five survived, with an average duration of survival of 128 ± 3 h. All cynomolgus monkeys in the control group died, with a duration of survival of 112 ± 2 h. Survival time was significantly longer with HBALSS treatment (P < 0.05). Moreover, the number, viability and function of hepatocytes were maintained at a high level with HBALSS. CONCLUSION: The novel hybrid bioartificial liver plays a significant role in liver support by significantly reducing serum biochemistry levels and extending animal survival time.
AIM: To evaluate a hybrid bioartificial liver support system (HBALSS) in cynomolgus monkeys with acute liver failure. METHODS: To establish a model of acute liver failure, 0.3 g/kg of D-galactosamine was injected intravenously into cynomolgus monkeys. Chinese human liver cells were introduced into a perfusion bioreactor to carry out hybrid bioartificial liver support treatment. Forty-eight hours after the injection, one group of cynomolgus monkeys received HBALSS care, and a second experimental group received no treatment. Clinical manifestations of all animals, survival time, liver and kidney functions and serum biochemistry changes were recorded. Simultaneous detection of the number, viability and function of hepatocytes in the hybrid bioartificial liver were also performed. RESULTS: Forty-eight hours after the injection of D-galactosamine, serum biochemistry levels were significantly increased, whereas albumin levels and the Fischer index were significantly reduced compared to baseline (all Ps < 0.05). Of the ten monkeys in the HBALSS treatment group, five survived, with an average duration of survival of 128 ± 3 h. All cynomolgus monkeys in the control group died, with a duration of survival of 112 ± 2 h. Survival time was significantly longer with HBALSS treatment (P < 0.05). Moreover, the number, viability and function of hepatocytes were maintained at a high level with HBALSS. CONCLUSION: The novel hybrid bioartificial liver plays a significant role in liver support by significantly reducing serum biochemistry levels and extending animal survival time.
Entities:
Keywords:
Acute liver failure; Chinese human liver cells; Cynomolgus monkey; Human liver cell; Hybrid bioartificial liver
Authors: C O Esquivel; E B Keeffe; G Garcia; J C Imperial; M T Millan; H Monge; S K So Journal: J Gastroenterol Hepatol Date: 1999-05 Impact factor: 4.029
Authors: Paul P C Poyck; Albert C W A van Wijk; Tessa V van der Hoeven; Dirk R de Waart; Robert A F M Chamuleau; Thomas M van Gulik; Ronald P J Oude Elferink; Ruurdtje Hoekstra Journal: J Hepatol Date: 2007-12-17 Impact factor: 25.083
Authors: Lei Cai; Jun Weng; Lei Feng; Guolin He; Jiasheng Qin; Zhi Zhang; Yang Li; Qing Peng; Zesheng Jiang; Mingxin Pan; Yi Gao Journal: Biomed Res Int Date: 2016-12-21 Impact factor: 3.411
Authors: Lei Feng; Lei Cai; Guo-Lin He; Jun Weng; Yang Li; Ming-Xin Pan; Ze-Sheng Jiang; Qing Peng; Yi Gao Journal: World J Gastroenterol Date: 2017-11-14 Impact factor: 5.742
Authors: Lei Feng; Guolin He; Lei Cai; Chaoyi Fu; Yang Li; Jun Weng; Xiaolin Huo; Qing Peng; Yi Gao Journal: Biomed Res Int Date: 2018-05-24 Impact factor: 3.411